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Abstract 
 
We report herein the synthesis and biological activities (cytotoxicity, leishmanicidal and trypanocidal) 
of six quinoline-chalcone and five quinoline-chromone hybrids. The synthesized compounds were 
evaluated against amastigotes forms of  L. (V)  panamensis which is the most prevalent Leishmania 
species in Colombia and Trypanosoma cruzi which is the major pathogenic species to humans. 
Cytotoxicity was evaluated against human U-937 macrophages. Compounds 8-12, 20, 23 and 24 
showed activity against L. (V) panamensis while compounds 9, 10, 12, 20 and 23 had activity against T. 
cruzi with EC50 values lower than 18 mg/Ml. 20 was the most active compound for both L. (V) 
panamensis and T. cruzi with EC50 of 6.11 ± 0.26 µg/mL (16.91 µM) and 4.09 ± 0.24 (11.32µM), 
respectively. All hybrids compounds showed better activity than the anti-leishmanial drug meglumine 
antimoniate. Compounds 20 and 23 showed higher actives than benznidazole, the current anti-
trypanosomal drug. Although these compounds showed  toxicity for  mammalian  U-937 cells, still  
have  potential  to  be  considered  as  candidates  to  antileishmanial or trypanocydal  drug 
development. 
 
 
 
Keywords: leishmaniasis; Chagas disease; antiprotozoal activity; cytotoxicity; quinoline; chalcone; 
chromone; hybrids 
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Introduction 
 
Neglected tropical diseases (NTD) are a cause of mortality in various developing countries of tropical 
and  subtropical  regions. These diseases are significant health problems in endemic countries, affecting 
more than one billion people worldwide (WHO, 2013). This situation is aggravated by increasing 
treatment failures with available drugs (Bhutta et al., 2014). NTD include, among others, Chagas’ 
disease (American trypanosomiasis) and leishmaniasis. These are parasitic diseases caused by the 
parasitic protozoan Trypanosoma cruzi (T. cruzi) and Leishmania species. These diseases affect more 
than 10 million people worldwide (Alvar et al., 2012; Nouvellet et al., 2015) L. (V) panamensis is one 
of the most prevalent Leishmania species involved in human cases of cutaneous leishmaniasis in 
Colombia (Alvar et al., 2012). Current chemotherapies are based on old drugs, pentavalent antimonials 
(meglumine antimoniate and sodium stibogluconate) to treat cutaneous leishmaniasis and nitroaromatic 
compounds (benznidazole and nifurtimox) for treatment of Chagas disease. Unfortunatelly, all of these 
drugs are not very effective in the chronic phase and have toxicity, side effects and parasite resistance 
(Den Boer et al., 2011; Keenan et al., 2015; Chatelain et al., 2011).     
 
    A quinolinic core is a structural feature of several bioactive compounds. Thus, this core is an 
interesting constituent for new drugs design. Anti-mycobacterial, anti-microbial, anti-convulsant, anti-
inflamatory, anti-tumoral, cardiovascular but also leishmanicidal and trypanocidal, are some biological 
activities exhibited by compounds having this heteroaromatic ring (Suresh et al., 2009; Nakayama et 
al., 2005; Tempone et al., 2005; Dietze et al., 2001; Mohammed et al., 2003; Vieira et al., 2008; 
Cardona et al., 2013; Palit et al., 2009; Franck et al., 2004; Coa et al., 2015). The antileishmanial 
activity of several chalcones has been reported (Kayser et al., 2001; Liu et al., 2003; Boeck et al., 
2006). The most promising of this class of compounds is licochalcone A, an oxygenated chalcone 
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isolated from the roots of the Chinese plant Glycyrrhiza spp, which inhibits the fumarate reductase, a 
selective target present in the mitochondria of the parasite (Chen et al., 2001). Similarly, chromones 
are important classes of compounds having versatile biological activities (Horton et al., 2003; 
Hadjeri et al., 2003; Ellis et al., 1972; Houghton et al., 2000; Mallick et al., 2011; Baloch et al., 
2012). Both moieties are well known for their antiprotozoal activity. Some synthetic chromones were 
effective against L. (L) donovani (Mallick et al., 2011) and L. (L) major (Baloch et al., 2012) in in 
vivo studies.  
 
    In the search for new therapeutic alternatives to treat cutaneous leishmaniasis and Chagas disease, in 
this work we designed and synthesized a series of quinoline-chalcone and quinoline-chromone hybrids 
and evaluated in vitro their cytotoxicity, leishmanicidal and trypanocidal activities. 
 
Material and Methods 
Chemistry 
General remarks 
Microwave reactions were carried out in a CEM Discover microwave reactor in sealed vessels 
(monowave, maximum power 300 W, temperature control by IR sensor, fixed temperature). 1H and 13C 
NMR spectra were recorded on a Varian instrument operating at 500 and 125 MHz, respectively. The 
signals of the deuterated solvent (CDCl3) were used as reference (the singlet at δ = 7.27 ppm for 1H 
NMR and the triplet centred at δ = 77.00 ppm for 13C NMR). Carbon atom types (C, CH, CH2, CH3) 
were determined by using the DEPT or APT pulse sequence. High resolution mass spectra were 
recorded using electrospray ionization mass spectrometry (ESI-MS). A QTOF Premier instrument with 
an orthogonal Z-spray-electrospray interface (Waters, Manchester, UK) was used operating in the  
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W-mode. The drying and cone gas was nitrogen set to flow rates of 300 and 30 L/h, respectively. 
Methanol sample solutions (ca. 1 × 10−5 M) were directly introduced into the ESI spectrometer at a 
flow rate of 10 µL/min. A capillary voltage of 3.5 kV was used in the positive scan mode, and the cone 
voltage set to Uc = 10 V. For accurate mass measurements, a 2 mg/L standard solution of leucine 
enkephalin was introduced via the lock spray needle at a cone voltage set to 85 V and a flow rate of  
30 μL/min. IR spectra were recorded on a Spectrum RX I FT-IR system (Perkin-Elmer, Waltham, MA, 
USA) in KBr disks. Silica gel 60 (0.063–0.200 mesh, Merck, Whitehouse Station, NJ, USA) was used 
for column chromatography, and precoated silica gel plates (Merck 60 F254 0.2 mm) were used for 
thin layer chromatography (TLC).  
 
General procedure for the synthesis of bromoalkyl derivatives  
    Quinoline or chromone  (1 mmol),  potassium  hydroxide  (1.5 mmol, 84.2 mg)  and  acetonitrile  (10 
mL),  were  placed  in  a  25  mL  flat-bottomed  flask  equipped  with  a  magnetic  stirring  bar.  The 
mixture was stirred and heated to reflux for a period of 5 min, under microwave irradiation. Then, 1,ω-
dibromoalkane (1.1 mmol) was added to the reaction mixture which was refluxed for 30 minutes (70 
W). The crude  reaction  mixture  was  concentrated  on  a  rotatory  evaporator and  the  residue  was  
purified  by column  chromatography  over  silica  gel  eluting  with  hexane  and  a  mixture  of  
hexane-ethyl acetate  (9:1 ratio) to obtain bromoalkyl derivatives in yields ranging between 42–80%. 
Monitoring of the reaction progress and product purification was carried out by TLC.   
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8-(3-bromopropoxy)quinoline (2): Yield 75% (0.75 mmol, 200 mg); brown oil. IR (cm−1): νmax  1570 
(C=CAr), 1500 (C=N), 1263 (C-O-C), 794 (C-HAr).  
1H-NMR (CDCl3): δ 2.20-2.30 (2H, m), 4.03 (2H, 
t, J = 5.3 Hz), 4.47 (2H, t, J = 5.6 Hz), 7.21 (1H, d, J = 6.2 Hz), 7.44-7.56 (3H, m), 8.20 (1H, dd, J = 
8.3, 1.5 Hz), 8.94 (1H, dd, J = 4.2, 1.5 Hz). 13C-NMR (CDCl3): δ 30.0 (CH2), 31.9 (CH2), 69.6 (CH2), 
111.6 (C), 120.6 (C), 121.7 (C), 126.8 (C), 129.6 (C), 136.2 (C), 140.7 (C), 149.4 (C), 154.8 (C). 
8-(4-bromobutoxy)quinoline (3): Yield 64% (0.64 mmol, 179 mg); dark yellow solid, M.p. 46-48°C. IR 
(cm−1): νmax  1593 (C=CAr), 1529 (C=N), 1240 (C-O-C), 835 (C-HAr). 1H-NMR (CDCl3): δ 2.17-2.27 
(4H, m), 3.57 (2H, t, J = 5.8 Hz), 4.29 (2H, t, J = 5.5 Hz), 7.09 (1H, d, J = 7.5 Hz), 7.39-7.53 (3H, m), 
8.17 (1H, dd, J = 8.3, 1.1 Hz), 9.01 (1H, dd, J = 4.2, 1.3 Hz). 13C-NMR (CDCl3): δ 27.7 (CH2), 29.5 
(CH2), 33.7 (CH2), 67.8 (CH2), 108.8 (C), 119.7 (C), 121.7 (C), 126.8 (C), 129.6 (C), 136.3 (C), 139.9 
(C), 149.2 (C), 154.5 (C). 
8-((5-bromopentyl)oxy) quinoline (4): Yield 51% (0.51 mmol, 150 mg); brown solid, M.p. 58-62°C. IR 
(cm−1): νmax  1595 (C=CAr), 1529 (C=N), 1288 (C-O-C), 829 (C-HAr). 1H-NMR (CDCl3): δ 1.69-1.82 
(2H, m), 1.97-2.07 (2H, m), 2.07-2.19 (2H, m), 3.50 (2H, t, J = 6.8 Hz), 4.29 (2H, t, J = 6.8 Hz), 7.10 
(1H, d, J = 7.5 Hz), 7.40-7.53 (3H, m), 8.17 (1H, dd, J = 8.2, 1.0 Hz), 8.99 (1H, dd, J = 4.2, 1.0 Hz). 
13C-NMR (CDCl3): δ 24.9 (CH2), 28.2 (CH2), 32.6 (CH2), 33.6 (CH2), 68.6 (CH2), 108.7 (C), 119.6 
(C), 121.6 (C), 126.7 (C), 129.6 (C), 136.0 (C), 140.3 (C), 149.4 (C), 154.7 (C). 
8-((8-bromooctyl)oxy) quinoline (5): Yield 80% (0.80 mmol, 269 mg); light brown oil. IR (cm−1): νmax  
1593 (C=CAr), 1529 (C=N), 1286 (C-O-C), 831 (C-HAr). 
1H-NMR (CDCl3): δ 1.33-1.50 (6H, m), 1.51-
1.64 (2H, m), 1.81-1.94 (2H, m), 1.99-2.11 (2H, m), 3.42 (2H, t, J = 6.9 Hz), 4.25 (2H, t, J = 6.9 Hz), 
7.08 (1H, d, J = 7.6 Hz), 7.36-7.52 (3H, m), 8.15 (1H, dd, J = 8.3, 1.5 Hz), 8.99 (1H, dd, J = 4.2, 1.6 
Hz). 13C-NMR (CDCl3): δ 26.0 (CH2), 28.1 (CH2), 28.7 (CH2), 29.0 (CH2), 29.3 (CH2), 32.8 (CH2), 
34.1 (CH2), 68.9 (CH2), 108.8 (C), 119.4 (C), 121.6 (C), 126.8 (C), 129.5 (C), 136.1 (C), 140.2 (C), 
149.2 (C), 154.8 (C). 
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8-((9-bromononyl)oxy)quinoline (6): Yield 75% (0.75 mmol, 263 mg); light brown oil. IR (cm−1): νmax  
1595 (C=CAr), 1531 (C=N), 1286 (C-O-C), 833 (C-HAr). 
1H-NMR (CDCl3): δ 1.31-1.52 (6H, m), 1.52-
1.66 (2H, m), 1.82-1.95 (2H, m), 2.00-2.13 (2H, m), 3.44 (2H, t, J = 6.9 Hz), 4.26 (2H, t, J = 6.9 Hz), 
7.10 (1H, d, J = 7.6 Hz), 7.38-7.53 (3H, m), 8.18 (1H, dd, J = 8.3, 1.3 Hz), 9.02 (1H, dd, J = 4.2, 1.3 
Hz). 13C-NMR (CDCl3): δ 26.1 (CH2), 28.2 (CH2), 28.7 (CH2), 29.0 (CH2), 29.4 (CH2) (x2), 32.8 
(CH2), 34.1 (CH2), 69.0 (CH2), 108.6 (C), 119.3 (C), 121.6 (C), 126.8 (C), 129.5 (C), 136.2 (C), 140.0 
(C), 149.2 (C), 154.8 (C). 
8-((12-bromododecyl)oxy)quinoline (7): Yield 67% (0.67 mmol, 263 mg); brown solid, M.p. 44-46°C. 
IR (cm−1): νmax  1597 (C=CAr), 1529 (C=N), 1259 (C-O-C), 829 (C-HAr). 1H-NMR (CDCl3): δ 1.23-
1.38 (6H, m), 1.37-1.49 (2H, m), 1.49-1.62 (2H, m), 1.79-1.93 (2H, m), 1.98-2.12 (2H, m), 3.42 (2H, t, 
J = 6.9 Hz), 4.25 (2H, t, J = 7.0 Hz), 7.07 (1H, d, J = 7.5 Hz), 7.35-7.51 (3H, m), 8.13 (1H, dd, J = 8.3, 
1.2 Hz), 8.98 (1H, dd, J = 4.2, 1.2 Hz). 13C-NMR (CDCl3): δ 26.1 (CH2), 28.2 (CH2), 28.8 (CH2), 29.0 
(CH2), 29.6 (CH2) (x3), 29.5 (CH2), 29.4 (CH2) (x2), 32.9 (CH2), 34.1 (CH2), 69.0 (CH2), 108.6 (C), 
119.3 (C), 121.5 (C), 126.8 (C), 129.5 (C), 136.0 (C), 140.3 (C), 149.2 (C), 154.9 (C). 
7-[(9-bromononyl)oxy]-4H-chromen-4-one (18): Yield 49% (0.49 mmol, 180 mg); light yellow solid, 
M.p. 60-62°C. IR (cm−1): νmax  1649  (C=O), 1602 (C=C), 1444 (C=CAr), 1234 (C-O-C), 813 (C-HAr).  
1H-NMR (CDCl3): δ 1.28-1.42 (10H, m), 1.42-1.55 (2H, m), 1.78-1.93 (2H, m), 3.43 (2H, t, J = 6.8 
Hz), 4.05 (2H, t, J = 6.5 Hz), 6.29 (1H, d, J = 6.0 Hz), 6.83 (1H, d, J = 2.3 Hz), 6.97 (1H, dd, J = 9.0, 
2.3 Hz), 7.80 (1H, d, J = 6.1 Hz), 8.11 (1H, d, J = 9.0 Hz). 13C-NMR (CDCl3): δ 25.9 (CH2), 28.1 
(CH2), 28.7 (CH2), 28.9 (CH2), 29.2 (CH2), 29.3 (CH2), 32.8 (CH2), 34.1 (CH2), 68.7 (CH2), 100.8 (C), 
112.9 (C), 114.9 (C), 118.6 (C), 127.1 (C), 154.9 (C), 158.3 (C), 163.7 (C), 177.1 (C=O).  
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7-[(12-bromododecyl)oxy]-4H-chromen-4-one (19): Yield 42% (0.42 mmol, 172 mg); light yellow 
solid, M.p. 58-60°C. IR (cm−1): νmax  1651  (C=O), 1605 (C=C), 1450 (C=CAr), 1238 (C-O-C), 812 (C-
HAr).  
1H-NMR (CDCl3): δ 1.22-1.39 (12H, m), 1.40-1.52 (4H, m), 1.79-1.90 (4H, m), 3.41 (2H, t, J = 
6.8 Hz), 4.05 (2H, t, J = 6.5 Hz), 6.30 (1H, d, J = 6.0 Hz), 6.83 (1H, d, J = 2.2 Hz), 6.97 (1H, dd, J = 
8.9, 2.2 Hz), 7.77 (1H, d, J = 6.0 Hz), 8.11 (1H, d, J = 8.9 Hz). 13C-NMR (CDCl3): δ 25.9 (CH2), 28.1 
(CH2), 28.7 (CH2), 28.9 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.5 (CH2) (x2), 32.8 (CH2), 33.9 
(CH2), 68.7 (CH2), 100.9 (C), 112.9 (C), 114.8 (C), 118.6 (C), 127.1 (C), 154.8 (C), 158.3 (C), 163.7 
(C), 177.1 (C=O).  
General procedure for the synthesis of quinoline-chalcone and quinoline-chromone hybrids  
    Chalcone or 8-hydroxyquinoline (0.75 mmol), potassium hydroxide (1 mmol) and acetonitrile (10 
mL), were placed in a 50 mL flat-bottomed flask equipped with a magnetic stirring bar. The mixture 
was stirred and heated to reflux for a period of 5 minutes, under microwave irradiation. Then, 
bromoalkylquinoline or bromoalkylchromenone (0.5 mmol) was added to the reaction mixture which 
was then refluxed for 30 minutes (70 W). The crude reaction mixture was concentrated on a rotatory 
evaporator and the residue was purified by column chromatography over silica gel eluting with hexane-
ethyl acetate to obtain quinoline-chalcone or quinoline-chromone hybrids in yields ranging 44-65% and 
34-70%, respectively. Monitoring of the reaction progress and product purification was carried out by 
TLC. 
(E)-3-(3,4-dimethoxyphenyl)-1-(4-(3-(quinolin-8-yloxy)propoxy)phenyl)prop-2-en-1-one (8): Yield 
65% (0.33 mmol, 155 mg); yellow solid, M.p. 62-64°C; IR (cm−1): νmax  1655 (C=O), 1599 (C=C), 
1510, (C=N) 1262 (C-O-C), 803 (C-HAr). 
1H-NMR (CDCl3): δ 2.51-2.59 (2H, m), 3.94 (3H, s), 3.96 
(3H, s), 4.37 (2H, t, J = 6.1 Hz), 4.48 (2H, t, J = 6.2 Hz), 6.90 (1H, d, J = 8.3 Hz), 7.01 (2H, d, J = 8.8 
Hz), 7.13 (1H, dd, J = 7.6, 1.0 Hz), 7.16 (1H, d, J = 2.0 Hz), 7.23 (1H, dd, J = 8.3, 2.0), 7.37-7.49 (4H, 
m), 7.75 (1H, d, J = 15.6 Hz), 8.01 (2H, d, J = 8.8 Hz), 8.14 (1H, dd, J = 8.3, 1.7 Hz), 8.96 (1H, dd, J = 
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4.4, 1.7 Hz). 13C-NMR (CDCl3): δ 29.1 (CH2), 56.0 (CH3) (x2), 65.0 (CH2), 65.4 (CH2), 109.0 (C), 
110.2 (C), 111.2 (C), 114.3 (C) (x2), 119.8 (C), 119.9 (C), 121.6 (C), 122.9 (C), 126.6 (C), 128.1 (C), 
129.5 (C), 130.7 (C) (x2), 131.3 (C), 135.9 (C), 140.4 (C), 144.0 (C), 149.2 (C), 149.3 (C), 151.3 (C), 
154.6 (C), 162.6 (C), 188.6 (C=O). ESI-MS: m/z 470.1967 [M + H]+, Calcd for C29H27NO5 : 470.1959  
(E)-3-(3,4-dimethoxyphenyl)-1-(4-(4-(quinolin-8-yloxy)butoxy)phenyl)prop-2-en-1-one (9): Yield 44% 
(0.22 mmol, 106.4 mg); yellow solid, M.p. 130-134°C; IR (cm−1): νmax  1659 (C=O), 1599 (C=C), 1512 
(C=N), 1262 (C-O-C), 814 (C-HAr). 
1H-NMR (CDCl3): δ 2.08-2.17 (2H, m), 2.20-2.29 (2H, m), 3.94 
(3H, s), 3.97 (3H, s), 4.21 (2H, t, J = 6.3 Hz), 4.36 (2H, t, J = 6.4 Hz), 6.91 (1H, d, J = 8.3 Hz), 6.99 
(2H, d, J = 8.8 Hz), 7.09 (1H, d, J = 7.6 Hz), 7.17 (1H, d, J = 1.8 Hz), 7.24 (1H, dd, J = 8.3, 1.7), 7.37-
7.50 (4H, m), 7.76 (1H, d, J = 15.6 Hz), 8.01 (2H, d, J = 8.9 Hz), 8.13 (1H, dd, J = 8.3, 1.9 Hz), 8.95 
(1H, dd, J = 4.2, 1.9 Hz). 13C-NMR (CDCl3): δ 25.7 (CH2), 26.1 (CH2), 56.0 (CH3) (x2), 67.9 (CH2), 
68.5 (CH2), 108.8 (C), 110.2 (C), 111.2 (C), 114.3 (C) (x2), 119.6 (C), 120.0 (C), 121.6 (C), 122.9 (C), 
126.6 (C), 128.1 (C), 129.5 (C), 130.7 (C) (x2), 131.2 (C), 135.9 (C), 140.5 (C), 144.0 (C), 149.2 (C), 
149.3 (C), 151.3 (C), 154.7 (C), 162.8 (C), 188.7 (C=O). ESI-MS: m/z 484.2124 [M + H]+, Calcd for 
C30H29NO5 : 484.2119  
(E)-3-(3,4-dimethoxyphenyl)-1-(4-((5-(quinolin-8-yloxy)pentyl)oxy)phenyl)prop-2-en-1-one (10): Yield 
56% (0.28 mmol, 139.3 mg); yellow solid, M.p. 220-224°C; IR (cm−1): νmax  1641 (C=O), 1593 (C=C), 
1513 (C=N), 1221 (C-O-C), 812 (C-HAr). 
1H-NMR (CDCl3): δ 1.73-1.88 (2H, m), 1.92-2.05 (2H, m), 
2.11-2.24 (2H, m), 3.94 (3H, s), 4.01 (3H, s), 4.13 (2H, t, J = 6.4 Hz), 4.32 (2H, t, J = 6.8 Hz), 6.94 
(1H, d, J = 8.5 Hz), 7.01 (2H, d, J = 8.7 Hz), 7.11 (1H, d, J = 7.5 Hz), 7.21 (1H, d, J = 1.5 Hz), 7.27 
(1H, dd, J = 8.5, 1.5), 7.37-7.53 (4H, m), 7.80 (1H, d, J = 15.5 Hz), 8.06 (2H, d, J = 8.7 Hz), 8.17 (1H, 
dd, J = 8.2, 1.1 Hz), 8.89 (1H, dd, J = 4.0, 1.1 Hz). 13C-NMR (CDCl3): δ 22.8 (CH2), 28.8 (CH2), 29.0 
(CH2), 56.0 (CH3) (x2), 68.0 (CH2), 68.7 (CH2), 108.7 (C), 110.1 (C), 111.2 (C), 114.3 (C) (x2), 119.6 
(C), 119.9 (C), 121.6 (C), 123.0 (C), 126.7 (C), 128.1 (C), 129.6 (C), 130.8 (C) (x2), 131.1 (C), 136.0 
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(C), 140.4 (C), 144.1 (C), 149.2 (C), 149.4 (C), 151.3 (C), 154.8 (C), 162.9 (C), 188.9 (C=O). ESI-MS: 
m/z 498.2280 [M + H]+, Calcd for C31H31NO5 : 498.2287  
(E)-3-(3,4-dimethoxyphenyl)-1-(4-((8-(quinolin-8-yloxy)octyl)oxy)phenyl)prop-2-en-1-one (11): Yield 
58% (0.29 mmol, 156.5 mg); yellow solid, M.p. 104-108°C; IR (cm−1): νmax  1657 (C=O), 1599 (C=C), 
1513 (C=N), 1258 (C-O-C), 816 (C-HAr). 
1H-NMR (CDCl3): δ 1.40-1.48 (2H, m), 1.48-1.54 (2H, m), 
1.54-1.62 (2H, m), 1.79-1.86 (2H, m), 2.01-2.09 (2H, m), 3.94 (3H, s), 3.96 (3H, s), 4.04 (2H, t, J = 6.5 
Hz), 4.26 (2H, t, J = 7.0 Hz), 6.90 (1H, d, J = 8.4 Hz), 6.97 (2H, d, J = 8.8 Hz), 7.07 (1H, d, J = 7.6 
Hz), 7.17 (1H, d, J = 1.9 Hz), 7.24 (1H, dd, J = 8.4, 2.0), 7.36-7.48 (4H, m), 7.76 (1H, d, J = 15.6 Hz), 
8.03 (2H, d, J = 8.9 Hz), 8.12 (1H, dd, J = 8.3, 1.7 Hz), 8.96 (1H, dd, J = 4.1, 2.0 Hz). 13C-NMR 
(CDCl3): δ 25.9 (CH2), 26.0 (CH2), 29.0 (CH2), 29.1 (CH2), 29.2 (CH2), 29.3 (CH2), 56.0 (CH3) (x2), 
68.2 (CH2), 69.0 (CH2), 108.6 (C), 110.2 (C), 111.2 (C), 114.3 (C) (x2), 119.4 (C), 119.9 (C), 121.5 
(C), 122.9 (C), 126.6 (C), 128.1 (C), 129.5 (C), 130.7 (C) (x2), 131.1 (C), 135.8 (C), 140.5 (C), 144.0 
(C), 149.2 (C), 149.3 (C), 151.3 (C), 154.7 (C), 162.9 (C), 188.7 (C=O). ESI-MS: m/z 540.2750 [M + 
H]+, Calcd for C34H37NO5 : 540.2742. 
(E)-3-(3,4-dimethoxyphenyl)-1-(4-((9-(quinolin-8-yloxy)nonyl)oxy)phenyl)prop-2-en-1-one (12): Yield 
49% (0.23 mmol, 127.4 mg); yellow solid, M.p. 84-88°C; IR (cm−1): νmax 1728 (C=O), 1655 (C=C), 
1601 (C=N), 1262 (C-O-C), 797 (C-HAr). 
1H-NMR (CDCl3): δ 1.35-1.51 (8H, m), 1.52-1.65 (2H, m), 
1.76-1.90 (2H, m), 2.01-2.13 (2H, m), 3.95 (3H, s), 3.98 (3H, s), 4.05 (2H, t, J = 6.5 Hz), 4.26 (2H, t, J 
= 7.1 Hz), 6.91 (1H, d, J = 8.3 Hz), 6.99 (2H, d, J = 8.8 Hz), 7.08 (1H, d, J = 7.5 Hz), 7.19 (1H, d, J = 
1.5 Hz), 7.26 (1H, dd, J = 8.3, 1.6), 7.36-7.51 (4H, m), 7.79 (1H, d, J = 15.5 Hz), 8.06 (2H, d, J = 8.8 
Hz), 8.14 (1H, dd, J = 8.3, 1.4 Hz), 8.97 (1H, dd, J = 4.2, 1.5 Hz). 13C-NMR (CDCl3): δ 26.0 (CH2), 
26.1 (CH2), 29.0 (CH2), 29.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 56.0 (CH3) (x2), 68.3 (CH2), 
69.0 (CH2), 108.6 (C), 110.1 (C), 111.1 (C), 114.3 (C) (x2), 119.4 (C), 119.9 (C), 121.6 (C), 123.0 (C), 
126.7 (C), 128.1 (C), 129.5 (C), 130.8 (C) (x2), 131.6 (C), 135.9 (C), 140.4 (C), 144.0 (C), 149.2 (C), 
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149.3 (C), 151.2 (C), 154.9 (C), 163.0 (C), 188.8 (C=O). ESI-MS: m/z 554.2987 [M + H]+, Calcd for 
C35H39NO5 : 554.2991. 
(E)-3-(3,4-dimethoxyphenyl)-1-(4-((12-(quinolin-8-yloxy)dodecyl)oxy)phenyl)prop-2-en-1-one (13): 
Yield 51% (0.26 mmol, 155 mg); yellow solid, M.p. 98-102°C; IR (cm−1): νmax  1656 (C=O), 1599 
(C=C), 1503 (C=N), 1258 (C-O-C), 801 (C-HAr). 
1H-NMR (CDCl3): δ 1.27-1.49 (14H, m), 1.50-1.64 
(2H, m), 1.75-1.93 (2H, m), 2.01-2.15 (2H, m), 3.98 (3H, s), 4.01 (3H, s), 4.08 (2H, t, J = 6.7 Hz), 4.28 
(2H, t, J = 7.1 Hz), 6.94 (1H, d, J = 8.4 Hz), 7.02 (2H, d, J = 8.8 Hz), 7.10 (1H, d, J = 7.5 Hz), 7.21 
(1H, d, J = 1.5 Hz), 7.28 (1H, dd, J = 8.3, 1.7), 7.38-7.53 (4H, m), 7.80 (1H, d, J = 15.7 Hz), 8.07 (2H, 
d, J = 8.8 Hz), 8.16 (1H, dd, J = 8.3, 1.6 Hz), 8.99 (1H, dd, J = 4.2, 1.6 Hz). 13C-NMR (CDCl3): δ 26.0 
(CH2), 26.1 (CH2), 29.0 (CH2), 29.1 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2) (x4), 56.0 (CH3) (x2), 
68.3 (CH2), 69.0 (CH2), 108.6 (C), 110.1 (C), 111.1 (C), 114.3 (C) (x2), 119.4 (C), 119.9 (C), 121.6 
(C), 123.0 (C), 126.7 (C), 128.1 (C), 129.5 (C), 130.8 (C) (x2), 131.1 (C), 135.9 (C), 140.5 (C), 144.1 
(C), 149.2 (C), 149.3 (C), 151.2 (C), 154.9 (C), 163.0 (C), 188.8 (C=O). ESI-MS: m/z 596.3410 [M + 
H]+, Calcd for C38H45NO5 : 596.3404. 
7-[4-(quinolin-8-yloxy)butoxy]-4H-chromen-4-one (20): Yield 34% (0.17 mmol, 61.4 mg); yellow 
solid, M.p. 160-164°C; IR (cm−1): νmax  1641 (C=O), 1593 (C=C), 1565 (C=N), 1437 (C=CAr), 1267 (C-
O-C), 820 (C-HAr). 
1H-NMR (CDCl3): δ 2.10-2.19 (2H, m), 2.20-2.29 (2H, m), 4.23 (2H, t, J = 6.2 Hz), 
4.36 (2H, t, J = 6.2 Hz), 6.27 (1H, d, J = 6.0 Hz), 6.85 (1H, d, J = 2.3 Hz), 6.94 (1H, dd, J = 9.0, 2.3 
Hz), 7.08 (1H, d, J = 7.6 Hz), 7.36-7.48 (3H, m), 7.76 (1H, d, J = 6.0 Hz), 8.07 (1H, d, J = 9.0 Hz), 
8.12 (1H, dd, J = 8.3, 1.5 Hz), 8.94 (1H, dd, J = 4.1, 1.5 Hz). 13C-NMR (CDCl3): δ 25.6 (CH2), 26.2 
(CH2), 68.4 (CH2), 68.5 (CH2), 100.1 (C), 108.7 (C), 112.9 (C), 114.8 (C), 118.6 (C), 119.7 (C), 121.5 
(C1), 126.6 (C), 127.1 (C), 129.5 (C), 135.8 (C), 140.4 (C), 149.3 (C), 154.6 (C), 154.7 (C), 158.2 (C), 
163.5 (C), 176.9 (C=O). ESI-MS: m/z 362.1392 [M + H]+, Calcd for C22H19NO4: 362.1390  
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7-{[5-(quinolin-8-yloxy)pentyl]oxy}-4H-chromen-4-one (21):Yield 61% (0.31 mmol, 116.4 mg); 
yellow solid, M.p. 134-138°C; IR (cm−1): νmax 1651 (C=O), 1597 (C=C), 1564 (C=N), 1443 (C=CAr), 
1263 (C-O-C), 824 (C-HAr). 
1H-NMR (CDCl3): δ 1.73-1.81 (2H, m), 1.92-2.01 (2H, m), 2.08-2.17 (2H, 
m), 4.02 (2H, t, J = 6.4 Hz), 4.29 (2H, t, J = 6.7 Hz), 6.26 (1H, d, J = 6.1 Hz), 6.81 (1H, d, J = 2.4 Hz), 
6.94 (1H, dd, J = 8.8, 2.4 Hz), 7.07 (1H, d, J = 7.8 Hz), 7.36-7.47 (3H, m), 7.76 (1H, d, J = 6.1 Hz), 
8.09 (1H, d, J = 8.8 Hz), 8.12 (1H, dd, J = 8.3, 1.6 Hz), 8.94 (1H, dd, J = 4.2, 1.6 Hz). 13C-NMR 
(CDCl3): δ 22.8 (CH2), 28.7 (CH2), 28.8 (CH2), 68.4 (CH2), 68.7 (CH2), 100.9 (C), 108.7 (C), 112.9 
(C), 114.8 (C), 118.6 (C), 119.6 (C), 121.5 (C), 126.6 (C), 127.1 (C), 129.5 (C), 135.8 (C), 140.5 (C), 
149.3 (C), 154.7 (C), 154.8 (C), 158.2 (C), 163.6 (C), 177.0 (C=O). ESI-MS: m/z 376.1549 [M + H]+, 
Calcd for C23H21NO4: 376.1542. 
7-{[8-(quinolin-8-yloxy)octyl]oxy}-4H-chromen-4-one (22): Yield 70% (0.35 mmol, 146.1 mg); yellow 
solid, M.p. 110-114°C; IR (cm−1): νmax  1655 (C=O), 1593 (C=C), 1593 (C=N), 1443 (C=CAr), 1263 (C-
O-C), 818 (C-HAr). 
1H-NMR (CDCl3): δ 1.42-1.54 (2H, m), 1.55-1.67 (2H, m), 1.80-1.93 (2H, m), 
2.02-2.19 (2H, m), 4.07 (2H, t, J = 6.6 Hz), 4.28 (2H, t, J = 7.0 Hz), 6.31 (1H, d, J = 6.1 Hz), 6.85 (1H, 
d, J = 2.3 Hz), 7.01 (1H, dd, J = 8.9, 2.3 Hz), 7.10 (1H, d, J = 7.5 Hz), 7.38-7.53 (3H, m), 7.80 (1H, d, 
J = 6.0 Hz), 8.13 (1H, d, J = 8.7 Hz), 8.16 (1H, dd, J = 8.0, 1.4 Hz), 8.99 (1H, dd, J = 4.2, 1.4 Hz). 13C-
NMR (CDCl3): δ 25.9 (CH2), 26.0 (CH2), 28.9 (CH2), 29.0 (CH2), 29.2 (CH2), 29.3 (CH2), 68.7 (CH2), 
68.9 (CH2), 100.8 (C), 108.6 (C), 112.9 (C), 114.9 (C), 118.6 (C), 119.4 (C), 121.6 (C), 126.7 (C), 
127.2 (C), 129.5 (C), 136.0 (C), 140.4 (C), 149.3 (C), 154.7 (C), 154.9 (C), 158.3 (C), 163.7 (C), 177.1 
(C=O). ESI-MS: m/z 418.2127 [M + H]+, Calcd for C26H27NO4: 418.2123. 
7-{[9-(quinolin-8-yloxy)nonyl]oxy}-4H-chromen-4-one (23): Yield 36% (0.18 mmol, 77.7 mg); yellow 
solid, M.p. 93-95°C; IR (cm−1): νmax  1659 (C=O), 1626 (C=C), 1594 (C=N), 1381 (C=CAr),  1265 (C-
O-C), 818 (C-HAr). 
1H-NMR (CDCl3): δ 1.31-1.45 (6H, m), 1.45-1.51 (2H, m), 1.51-1.60 (2H, m), 
1.78-1.86 (2H, m), 2.01-2.08 (2H, m), 4.03 (2H, t, J = 6.5 Hz), 4.25 (2H, t, J = 6.9 Hz), 6.27 (1H, d, J = 
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6.0 Hz), 6.82 (1H, d, J = 2.3 Hz), 6.96 (1H, dd, J = 8.9, 2.3 Hz), 7.07 (1H, d, J = 7.8 Hz), 7.36-7.48 
(3H, m), 7.76 (1H, d, J = 6.0 Hz), 8.11 (1H, dd, J = 8.1, 1.0 Hz), 8.13 (1H, d, J = 8.5 Hz), 8.96 (1H, dd, 
J = 4.2, 1.4 Hz). 13C-NMR (CDCl3): δ 25.9 (CH2), 26.0 (CH2), 28.9 (CH2), 29.0 (CH2), 29.2 (CH2), 
29.3 (CH2), 29.4 (CH2), 68.7 (CH2), 69.0 (CH2), 100.8 (C), 108.6 (C), 112.9 (C), 114.8 (C), 118.6 (C), 
119.3 (C), 121.5 (C), 126.6 (C), 127.1 (C), 129.5 (C), 135.9 (C), 140.4 (C), 149.2 (C), 154.7 (C), 154.9 
(C), 158.2 (C), 163.7 (C), 177.0 (C=O). ESI-MS: m/z 432.2175 [M + H]+, Calcd for C27H29NO4 : 
432.2173. 
7-{[12-(quinolin-8-yloxy)dodecyl]oxy}-4H-chromen-4-one (24):Yield 61% (0.31 mmol, 146.8 mg); 
yellow solid, M.p. 98-100°C; IR (cm−1): νmax  1651 (C=O), 1622 (C=C), 1596 (C=N), 1441 (C=CAr), 
1263 (C-O-C), 817 (C-HAr). 
1H-NMR (CDCl3): δ 1.24-1.43 (12H, m), 1.44-1.50 (2H, m), 1.51-1.60 
(2H, m), 1.78-1.87 (2H, m), 1.99-2.08 (2H, m), 4.04 (2H, t, J = 6.6 Hz), 4.24 (2H, t, J = 7.1 Hz), 6.27 
(1H, d, J = 6.1 Hz), 6.82 (1H, d, J = 2.1 Hz), 6.96 (1H, dd, J = 8.8, 2.0 Hz), 7.06 (1H, d, J = 7.7 Hz), 
7.34-7.48 (3H, m), 7.76 (1H, d, J = 6.1 Hz), 8.10 (1H, dd, J = 8.1, 1.2 Hz), 8.12 (1H, d, J = 8.2 Hz), 
8.95 (1H, dd, J = 4.2, 1.2 Hz). 13C-NMR (CDCl3): δ 25.9 (CH2), 26.0 (CH2), 28.9 (CH2), 29.0 (CH2), 
29.3 (CH2), 29.41 (CH2), 29.47 (CH2), 29.48 (CH2), 29.49 (CH2), 29.5 (CH2), 68.7 (CH2), 69.0 (CH2), 
100.9 (C), 108.6 (C), 112.9 (C), 114.8 (C), 118.6 (C), 119.3 (C), 121.5 (C), 126.6 (C), 127.1 (C), 129.5 
(C), 135.8 (C), 140.5 (C), 149.2 (C), 154.7 (C), 154.9 (C), 158.3 (C), 163.7 (C), 177.0 (C=O). ESI-MS: 
m/z 474.2644 [M + H]+, Calcd for C30H35NO4: 474.2642. 
 
Biological activity assays 
The compounds were subjected to evaluation of in vitro cytotoxicity on U937 human cells and 
leishmanicidal and trypanocidal activities on intracellular amastigotes of L.  (V) panamensis and T. 
cruzi.  
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In vitro Cytotoxicity  
    The cytotoxic activity of the compounds was assessed based on the viability of the human 
promonocytic cell line U-937 (ATCC CRL-1593.2TM) evaluated by the MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay following the methodology described previously (Taylor 
et al., 2011). Briefly, cells  grown in tissue flasks were harvested and washed with phosphate buffered 
saline (PBS) by centrifuging. Cells were counted and adjusted at 1 ×106 cells/mL of RPMI-1640 
supplemented with complete 10% Fetal Bovine Serum (FBS) and 1% antibiotics (100 U/mL penicillin 
and 0.1 mg/mL streptomycin). One hundred µL were dispensed into each well of a 96-well cell-culture 
plate and then 100 mL of RPMI-1640 and the corresponding concentrations of the compounds were 
added, starting at 200 µg/mL in duplicate. Plates were incubated at 37 °C, 5% CO2 during 72 h in the 
presence of extracts. The effect of compounds was determined by measuring the activity of the 
mitochondrial dehydrogenase by adding 10 µL/well of MTT solution (0.5 mg/mL) and incubation at 37 
°C for 3h. The reaction was stopped by adding 100 µL/well of 50% isopropanol solution with 10% 
sodium dodecyl sulfate and 30 min incubation. Cell viability was determined based on the quantity of 
formazan produced according to the intensity of color (absorbance) registered as optical densities (O.D) 
obtained at 570 nm in a spectrophotometer (Varioskan™ Flash Multimode Reader - Thermo Scientific, 
USA). Cells cultured in absence of compounds were used as control of viability (negative control), 
while meglumine antimoniate (Sbv) and amphotericin B (AmB) were used as control for cytotoxicity 
(non-cytotoxic and cytotoxic drugs, respectively). Assays were conducted in two independent runs with 
three replicates per each concentration tested. 
 
In vitro leishmanicidal activity 
    The activity of compounds was evaluated on intracellular amastigotes of L. (V) panamensis 
transfected with the green fluorescent protein gene (MHOM/CO/87/UA140pIR-GFP) (Pulido et al., 
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2012). The effect of each extract was determined according to the inhibition of the infection evidenced 
by both decrease of the infected cells and decrease of intracellular parasite load. Briefly, U-937 human 
cells at a concentration of 3 × 105 cells/mL in RPMI 1640 and 0.1 μg/mL of phorbol-12-myristate-13-
acetate (PMA) were dispensed into each well of a 24-well cell culture plate and then infected with 5 
days-old promastigotes in a 15:1 parasites per cell ratio. Plates were incubated at 34 °C, 5% CO2 during 
3h and cells were washed two times with PBS to eliminate not internalized parasites. One mL of fresh 
RPMI 1640 supplemented with 10% FBS and 1% antibiotics was added into each well, cells were 
incubated again to guarantee multiplication of intracellular parasites. After 24 h of infection, culture 
medium was replaced by fresh culture medium containing each compound at 20 μg/mL or lower (based 
on the cytotoxicity showed previously by each compound) and plates were incubated at 37 °C, 5% 
CO2. After 72 h, inhibition of the infection was determined. For this, cells were removed from the 
bottom plate with a trypsin/EDTA (250 mg) solution; recovered cells were centrifuged at 1100 rpm 
during 10 min at 4 °C, the supernatant was discarded and cells were washed with 1 mL of cold PBS 
and centrifuged at 1100 rpm during 10 min at 4 °C. The supernatant was discarded and cells were 
suspended in 500 μL of PBS and analyzed by flow cytometry (FC 500MPL, Cytomics, Brea, CA, US. 
All determinations for each extract and standard drugs were carried out in triplicate, in two independent 
experiments (Buckner et al., 1996; Pulido et al., 2012). Activity of tested extracts was carried out in 
parallel with infection progress in culture medium alone and in culture medium with AmB and Sbv as 
antileishmanial drugs (positive controls). Compounds that showed percentages of inhibition higher than 
50% to 20 or fewer μg/mL were then evaluated at four additional concentrations to determine the  
effective concentration 50 (EC50). Here, infected cells were exposed against each concentration of 
compounds during 72 h; then, cells were removed and tested by flow cytometry as described before.  
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In vitro Trypanocidal Activity  
    Compounds were tested on intracellular amastigotes of T. cruzi, Tulahuen strain transfected with β-
galactosidase gene (donated by Dr. F. S. Buckner, University of Washington) (Buckner et al., 1996). 
The activity was determined according to the ability of the extract to reduce the infection of U-937 
cells by T. cruzi as described elsewhere (Insuasty et al., 2015). Following the procedure described 
above, anti-T. cruzi  activity was initially screened at a single concentration of 20 mg/mL. In this case, 
100 μL of U-937 human cells at a concentration of 2.5 × 105 cells/mL in RPMI-1640, 10% SFB and 0.1 
μg/mL of PMA were placed in each well of  96-well plates and then infected with phase growth 
epimastigotes in 5:1 (parasites per cell) ratio and incubated at 34 °C, 5% CO2. After 24 hours of 
incubation, 20 μg/mL of each extract were added to infected cells. After 72 h of incubation, the effect 
of all extracts on viability of intracellular amastigotes was determined by measuring the β-galactosidase 
activity by spectrophotometry adding 100 μM CPRG and 0.1% nonidet P-40 to each well. After 3 h of 
incubation, plates were read at 570 nm in a spectrophotometer (Varioskan™ Flash Multimode Reader - 
Thermo Scientific, USA) and intensity of color (absorbance) was registered as O.D. Extracts that 
showed inhibition percentages higher than 50% were evaluated again at four concentrations selected 
according to the LC50 previously obtained for each compound. Infected cells exposed to benznidazol 
(BNZ) were used as control for antitrypanosomal activity (positive control) while infected cells 
incubated in culture medium alone were used as control for infection (negative control). Non-specific 
absorbance was corrected by subtracting the O.D of the blank. Determinations were done by triplicate 
in at least two independent experiments (Insuasty et al., 2015). 
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Statistical Analysis  
Cytotoxicity was determined according to the percentages of viability and mortality registered to 
each compound an concentration, including amphotericin B, meglumine antimoniate and culture 
medium alone. Percentage of viability was calculated by Equation 1, where the O.D of control, 
corresponds to 100% of viability.  
% Viability = (O.D Exposed cells) / (O.D Control cells) × 100 (1) 
In turn, mortality percentage corresponds to 100%–% viability. 
 
Results were expressed as 50 lethal concentrations (LC50) that corresponds to the concentration 
necessary to eliminate 50% of cells and calculated by Probit analysis (Finney, 1978). The degree of 
toxicity was graded according to the LC50 value using the following scale: high cytotoxicity: LC50 < 
100 μg/mL; moderate cytotoxicity: LC50 > 100 to < 200 μg/mL and potentially non-cytotoxicity: LC50 > 
200 μg/mL. 
On the other hand, anti-leishmanial activity was determined according to the percentage of infected 
cells and parasite load, obtained for each experimental condition by flow cytometry. The percentage of 
infected cells was determined as the number of positive events evidenced by green fluorescence  
(parasites) and Forward Scatter (FSC) using dotplot analysis, while, the parasitic load was determined 
by analysis of mean fluorescence intensity (MFI) of fluorescent parasites (Pulido et al., 2012). The 
parasite inhibition was calculated by equation 2, where the MFI of control, corresponds to 100% of 
parasites.  
% Parasite = (MFI Exposed parasites) / (MFI Control parasites) × 100 (2) 
In turn, inhibition percentage corresponds to 100% – % Parasites. Results of leishmanicidal activity 
were expressed as EC50 determined by the Probit analysis (Finney, 1978).  
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Similarly, trypanocidal activity was determined according to the percentage of infected cells and 
parasite load obtained for each experimental condition by colorimetry. Parasite inhibition was 
calculated by equation 3, where the O.D of control corresponds to 100% of infection.  
% Infection = (O.D Exposed parasites) / (O.D Control parasites) × 100 (3) 
     In turn, percentage of inhibition of infection corresponds to 100% – % of Infection.  
Results of anti-leishmanial and anti-trypanocidal activities were expressed as EC50 determined by the 
Probit analysis (Finney, 1978). The leishmanicidal or trypanocidal activities were graded according to 
the EC50 value using the following scale: High activity: EC50 < 25 μg/mL, moderate activity: EC50 > 25 
to < 50 μg/mL; potentially non activity: EC50 > 50 μg/mL. 
The selectivity index (SI), was calculated by dividing the cytotoxic activity and the leishmanicidal 
or trypanocidal activity using the following formula: SI = CL50/CE50. Cytotoxic compound: LC50<100 
µg/mL.  
 
Results and discussion 
Chemistry 
Quinoline-chalcone  hybrids  8-13  were  obtained  via  microwave  assisted  Williamson etherification  
(Peng et al., 2002; Otero et al., 2014) between  bromoalkylquinoline  2-7  and  3,4-dimethoxy-4'-
hydroxychalcone. Reaction yields ranged between 44% and 65%. Chalcone was prepared using a 
previously described method (Peyman et al., 2004) (Scheme 1). Compounds 2-7 were obtained using 
the same method from 8-hydroxyquinoline and dibromoalkanes with different numbers of carbon 
atoms with yields between 51% and 80%. 
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    Quinoline-chromone  hybrids  were  obtained  following  the  same  synthetic strategy  (Scheme  1).  
Initially,  7-hydroxychromone was treated with potassium hydroxide and 1,ω-dibromoalkanes (ω = 3, 
4, 5, 7, 9 and 12) to obtain the respective bromoalkyl derivatives 15-19 in yields similar to previous 
reports (Otero et al., 2014; Li et al., 2013) but in significantly shorter times. These compounds were 
coupled with quinoline to produce compounds 20-24 in 34-70%  yields.  Remarkably,  low  yields  
were  obtained  when  bromoalkylquinoline analogues were used as tactical variants. 
 
 
Scheme 1 Synthetic pathway to quinoline-chalcone and quinoline-chromone hybrids. 
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Leishmanicidal, trypanocidal and cytotoxic activities 
The effect of quinoline-chalcone and quinolone-chromone hybrids on cell growth and viability was 
assessed in human macrophages (U-937 cells) (Pulido et al., 2012) which are the host cells for L. (V) 
panamensis and T. cruzi parasites. On the other hand, the antiparasite activity of these compounds was 
tested on intracellular amastigotes of L. (V.) panamensis (Taylor et al., 2011) and T. cruzi (Buckner et 
al., 1996; Insuasty et al., 2015) according to the ability of these compounds to reduce the amount of 
parasite inside infected macrophages. Results are summarized in the  Table 1. 
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Table 1 In vitro cytotoxicity and antiprotozoal activity of quinoline-chalcone and quinoline-chromone 
hybrids 
 
Compound 
Cytotoxicity 
(U-937 cells) 
Leishmanicidal activity  
 
 Trypanocidal activity  
 
LC50 a EC50 b SIc  EC50 SI 
8  39.6 + 1.5, 84.34 11.79 + 0.34, 25.11 3.36  35.08 + 4.17, 74.71 1.13 
9 16.1 + 0.9, 33.29 6.24 + 0.14, 12.90 2.58  17.62 + 1.56, 36.44 0.91 
10 23.5 + 2.4, 47.23 12.37+ 0.93, 24.86 1.90  15.79 + 1.47, 31.73 1.49 
11 16.7 + 1.4, 30.94 8.53 + 0.69, 15.81 1.96  37.61 + 4.07, 69.69 0.44 
12 >40, 72.24 16.41 + 2.47, 29.64 >2.43  15.12 + 1.75, 27.30 >2.64 
13 69.2 + 9.3, 116.15 22.0 + 4.47, 36.93 3.15  54.95 + 5.47, 92.23 1.26 
20 5.4 + 0.9, 14.94 6.11 + 0.26, 16.91 0.89  4.09 + 0.24, 11.32 1.33 
21 113.5 + 16.3, 302.33 48.29 + 8.18, 128.63 2.35  40.70 + 7.40, 108.41 2.79 
22 121.4 + 9.3, 290.77 21.54 + 6.47, 51.59 5.64  28.43 + 2.77, 68.09 4.27 
23  4.1 + 0.2, 9.50 7.35 + 1.15, 17.03 0.56  >2, >4.63 2 
24 71.9 + 8.9, 151.81 16.18 + 1.45, 34.16 4.89  >20, >42.23 3.95 
3,4-dimethoxy-4'-
hydroxychalcone 
4.1 + 0.3, 14.42 2.36 + 0.37, 8.30 1.75  >2, >7.03 2 
8-hydroxyquinoline (1)  0.2 + 0.01, 1.38 0.36+ 0.02, 2.48 0.62  0.34+ 0.07, 2.34 0.66 
7-hydroxychromone (14) 132.5 + 25.7, 814.11 116.49 + 13.27, 718.45 1.14  18.23 + 2.62, 112.43 7.27 
Meglumine antimoniate 416.4 + 66.6 9.4 + 2.1  44.3  NAd NAd 
Amphotericin B  42.1 + 2.0, 45.6 0.05 + 0.01, 0.054 842  NAd NAd 
Benznidazole 179.0 ± 4.2, 687.8 NAd NAd  10.5 ± 1.8, 40.3 17.0 
Data represent mean value +/- standard deviation; a LC50: Lethal Concentration 50 in μg/mL, μM;  b EC50: Effective 
Concentration 50 in μg/mL, μM; c SI: Selectivity Index = LC50 / EC50; dNA: Not applicable. Active compounds: EC50 
< 25 μg/mL 
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    All compounds, amphotericin B and benznidazole with exception of 21, 22 and chromone, were 
highly cytotoxic to U-937 cells showing LC50 < 100.0 μg/mL (Table 1). Compounds 21, 22 and 
chromone, showed moderate cytotoxicity evidenced by  LC50 values higher than 100.0 μg/mL. In turn, 
meglumine antimoniate showed no cytotoxicity (LC50 > 200.0 μg/mL). 
    The anti-leishmanial and anti-trypanocidal activities were measured by determining the effective 
concentration 50 (EC50) that corresponds to the concentration of drug that gives the half-maximal 
reduction of the amount of intracellular parasites (Table 1). Dose-response relationship showed that 
compounds 8-12, 20, 23, 24, chalcone and quinoline were highly active against intracellular 
amastigotes of L. (V) panamensis with EC50 < 20 μg/mL. The most actives hybrids compounds were 
20, 9,  23 and 11 with an EC50 of 6.11 ± 0.26 μg/mL (16.91 µM), 6.24 ± 0.14 μg/mL (12.90 µM),  7.35 
± 1.15 μg/mL (17.03 µM) and 8.53 ± 0.69 μg/mL (15.81 µM) respectively, followed by 8, 10, 12 and 
24 with an EC50 of 11.79 + 0.34  μg/mL (25.11 µM), 12.37+ 0.93 μg/mL (24.86 µM), 16.41 + 2.47 
μg/mL, 29.64 µM 16.18 + 1.45 μg/mL (34.16 µM). As expected, the leishmanicidal drugs amphotericin 
B and meglumine antimoniate showed activity with low EC50 values.  
 
    In turn, compounds 20, 23, chalcone and quinoline were highly active against intracellular 
amastigotes of T. cruzi with EC50 of 4.09 + 0.24 μg/mL (11.32 µM), >2 μg/mL (>4.63 µM), >2 μg/mL 
( >7.03 µM) 0.34+ 0.07 μg/mL (2.34 µM) respectively, followed by compounds 9, 10, 12 and 
chromone with an EC50 of 17.62 + 1.56 μg/mL (36.44 µM), 15.79 + 1.47 μg/mL (31.73 µM), 15.12 + 
1.75 μg/mL (27.30 µM) and 18.23 + 2.62 μg/mL (112.43 µM) respectively. In this case, benznidazole 
showed activity with an EC50 of 10.5 ± 1.8 μg/mL (40.3 µM). 
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    The anti-leishmanial activity of compounds 8-13, 21, 22, 24, chalcone  and chromone and anti-
trypanocidal activity of compounds 8, 10, 12, 13, 20-24 and chromone were higher than their 
cytotoxicity. Thus, the SI (Selectivity Index) values calculated for these compounds were 1 (Table 1).   
 
    As demonstrated elsewhere, amphotericin B and meglumine antimoniate have very high SI values. 
Although all hybrid compounds showed better activity than meglumine antimoniate and the anti-
trypanocidal activity of compounds 20 and 23 were higher than benznidazole, the SI of these 
compounds is affected by their high cytotoxicity. These results suggest that biological activity of the 
quinoline derivatives reported here, with exception of 20 and 23, is selective, being more active against 
L. (V) panamensis than U-937 cells. On the other hand, compounds 8, 10, 12, 13, 20-24 were more 
actives against T. cruzi parasites than U-937 cells.  
 
    There is not a clear relationship between the antiprotozoal activity and the length of the alkyl linker, 
because as the chain length increase (increased lipophilicity), the activity does not show a definite 
tendency. All quinoline-chalcone hybrids were less cytotoxic and less active than the parent subunits. 
However, a synergistic effect of the parent subunits was observed in the quinoline-chromone hybrids in 
comparison with the unlinked cases, due to decreased cytotoxicity based on quinoline and increased 
activity based chromone. One possible mechanism of action for these compounds may be formulated in 
terms of conjugated addition  of  nucleophilic  amino  acid  residues present  in  target  enzymes  of   
Leishmania e.g. such cysteine  proteases (Mottram et al., 2004) in a Michael addition (Cardona et al., 
2014).  
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Conclusion 
The synthesis, anti-leishmanial and anti-trypanocidal screening of eleven quinoline derivatives are 
reported. Several of the synthetic compounds have potential as templates for drugs development. Eight 
of them were active against L. (V) panamensis (8-12, 20, 23 and 24) and five of them against T. cruzi 
(9, 10, 12, 20 and 23) with EC50 values lower than 18 μg/mL, 20 being the most active compound for 
both L. (V) panamensis and T. cruzi. All hybrid compounds showed better activity than meglumine 
antimoniate and compounds 20 and 23 showed higher actives than benznidazole. Studies on an animal 
model of leishmaniasis are needed to confirm the results observed in vitro. These compounds were 
toxic for  mammalian  U-937 cells, however  they may still have  potential  to  be  considered  as  
candidates  to  antileishmanial  drug development.  More  studies  on  toxicity  using  other  cell  lines  
are  needed  to  discriminate whether  the  toxicity  shown  by  these  compounds  is  specific against  
tumor  or  non-tumor  cells. Moreover, Michael acceptor  moieties  may  modify  the  parasitic  activity  
and  cytotoxicity.  The mechanism of action of these promising compounds also needs to be addressed.  
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